Neue Chemotherapien und kombinierte Immunochemotherapeutische Verfahren beim malignen Melanom

  • Rudolf Stadler
  • Constantin E. Orfanos
Conference paper
Part of the Der Hautarzt book series (VDGDERMATOLOGIE, volume 36)

Zusammenfassung

Das maligne Melanom ist ein besonders bösartiger Tumor mit hohem Metastasierungsrisiko. Es steht aufgrund seiner kontinuierlich zunehmenden Inzidenz und Mortalität in den letzten 10 Jahren im Mittelpunkt des Interesses der Dermatoonkologie [22, 24, 26, 65].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    AI Sarraf M, Fletchr W, Ioshi N. (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group study. Cancer Treat Rep 66: 31–35Google Scholar
  2. 2.
    Balch CM, Hersey P (1985) Current status of adjuvant therapy. In: Balch CM, Milton GW (eds) Cutaneous melanoma. Clinical management and treatment results worldwide. JB Lippincott Co., Philadelphia, pp 197–218Google Scholar
  3. 3.
    Banzet P, Jacquillat U, Klayat D et al. (1990) Chemotherapy for disseminated malignant melanoma: Monochemotherapy for fotemustine or combination with dacarbazine. Proceedings of ASCO Vol 9: 283 (A)Google Scholar
  4. 4.
    Barranco SC, Luke JK, Romsdahl MM, Humphrey RM (1973) Bleomycin as a possible synchronizing agent for human tumor cells in vivo. Cancer Res 33: 882–887PubMedGoogle Scholar
  5. 5.
    Bellet RE, Mastrangelo MJ, Berd D et al. (1979) Chemotherapy of metastatic malignant melanoma. In: Clark WH jur, Goldmann LI, Mastrangelo MJ (eds) Human malignant melanoma. Grüne and Stratton, New York San Francisco London, pp 325–354Google Scholar
  6. 6.
    Bergmann L (1989) Malignant melanoma-prognosis and actual treatment strategies with chemotherapy and biological response modifiers. Eur J Cancer Oncol 256 (Suppl 3): 31–36Google Scholar
  7. 7.
    Clemens MJ, McNurlan MA (1985) Regulation of cell proliferation and differentiation by interferon. Biochem J 226: 345–360PubMedGoogle Scholar
  8. 8.
    Coates A, Ralbins W, Bersey P, Swanson C (1985) Phase II trial of recombinant alpha-2 interferon in malignant melanoma. Proc 3rd Eur Conf Clin Oncol Cancer Nursing Stockholm, p 18Google Scholar
  9. 9.
    Creagan ET, Ahmann C, Green SJ et al. (1984a) Phase II study of „low dose” recombinant leukocyte A interferon (rlFN-alpha-A) in disseminated malignant melanoma. Am J Clin Oncol 2: 1002–1004Google Scholar
  10. 10.
    Creagan ET, Ahmann DL, Green SJ et al. (1984b) Phase II study of recombinant leukocyte A interferon (rlFN-alpha-A) in disseminated malignant melanoma. Cancer 54: 2844–2849PubMedCrossRefGoogle Scholar
  11. 11.
    Creagan ET, Ahmann DL, Green SJ et al. (1985) Phase II study of recombinant leukocyte A interferon (r/FN-alpha-A) plus Cimetidine in disseminated malignant melanoma.Am J Clin Oncol 3: 977–981Google Scholar
  12. 12.
    Creagan ET, Loprinzi CL, Ahmann DL, Schaid DJ (1988) A phase I—II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon gamma in patients with metastatic malignant melanoma. Cancer 62: 2472–2474PubMedCrossRefGoogle Scholar
  13. 13.
    Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM (1986) Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep 70: 619–624PubMedGoogle Scholar
  14. 14.
    Czarnetzki BM, Aragon V, Bröcker EB. (1986) Adjuvante Polychemotherapie zusätzlich zur radikalen operativen Behandlung regionaler Lymphknotenmetastasen beim malignen Melanom. Dt Med Wschr 11:732– 736Google Scholar
  15. 15.
    Czarniecki CW, Fennie CW, Powers DB, Estell DA (1984) Synergistic antiviral and antiproliferative activities of Escherichia coli derived human alpha, beta and gamma interferons. J Virol 49: 490–496PubMedGoogle Scholar
  16. 16.
    Dorval T, Palangie T, Joure M et al. (1986) Clinical phase II trial of recombinant DNA interferon in patients with metastatic malignant melanoma. Cancer 58: 215–218PubMedGoogle Scholar
  17. 17.
    Elsässer-Beile U, Dress N, Neumann HA, Schöpf E (1987) Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma. J Cancer Res Clin Oncol 113: 273–278PubMedCrossRefGoogle Scholar
  18. 18.
    Elsässer-Beile U, Garbe C, Stadler R et al. (1989) Adjuvante Therapie mit rekombiniertem Interferon alpha-2 beim metastasierten malignen Melanom. Hautarzt 40: 266–270PubMedGoogle Scholar
  19. 19.
    Elsässer-Beile U, Schöpf E, Neumann HA, Drews H, Hundhammer K, Balsa BR (1987) Rekombiniertes Lymphozyten- A-Interferon beim metastasierenden malignen Melanom. Dt Med Wschr 112: 373–377CrossRefGoogle Scholar
  20. 20.
    Epenetos AA, Kosma C (1989) Monoclonal antibodies for imaging and therapy. Br J Cancer 59: 152–155PubMedCrossRefGoogle Scholar
  21. 21.
    Fiedler H, Hetschko I, Wohlrab W et al. (1990) Ergebnisse einer randomisierten Polychemotherapiestudie beim malignen Melanom. Hautarzt 41: 369–374PubMedGoogle Scholar
  22. 22.
    Garbe C, Bertz J, Orfanos CE (1986a) Malignes Melanom: Zunahme von Inzidenz und Mortalität in der Bundesrepublik Deutschland. Z Hautkr 61: 1751–1764Google Scholar
  23. 23.
    Garbe C, Büttner P, Bertz J et al. (1990) Die Prognose des rimären malignen Melanoms. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. W Zuckschwerdt Verlag, München, S 41: 69Google Scholar
  24. 24.
    Garbe C, Bertz J, Orfanos CE (1987) Das maligne Melanom im deutschsprachigen Raum in den 80er Jahren. Hautarzt 38: 639–644PubMedGoogle Scholar
  25. 25.
    Garbe C, Günther-Eymann K, Stadler R, Orfanos CE (1988) Adjuvante Chemotherapie des malignen Melanoms mit DTIC. Hautarzt 39: 205–212PubMedGoogle Scholar
  26. 26.
    Garbe C, Wiebelt H, Orfanos CE (1989) Change of epidemiological characteristica of malignant melanoma during the years 1962-1972 and 1983-1986 in the Federal Republic of Germany. Dermatologica 1978: 131–135CrossRefGoogle Scholar
  27. 27.
    Garbe C, Stadler R, Orfanos CE (1989) Lokalrezidive und Metastasierung bei dünnen malignen Melanomen (1 mm). Hautarzt 40: 337–343PubMedGoogle Scholar
  28. 28.
    Garbe C, Stadler R, Orfanos CE (1986) Prognose-orientierte Therapie bei malignem Melanom. Neuere Konzepte. Hautarzt 37: 365–372Google Scholar
  29. 29.
    Garbe C, Stadler R, Zouboulis Ch, Orfanos CE (1988) Wachstumshemmung von Melanomzellen in vitro. Hautarzt (Suppl VIII ) 39: 269–270Google Scholar
  30. 30.
    Goldberg RM, Ayoob A, Silgals R et al. (1985) Phase II trial of lymphoblastoid interferon in metastatic malignant melanoma. Cancer Treat Rep 69: 813–816PubMedGoogle Scholar
  31. 31.
    Goodman GE, Beaumier P, Hellstroem I, Fernyhough B, Hellstroem KE (1985) Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 3: 340–352PubMedGoogle Scholar
  32. 32.
    Green JA, Smith K, Eccles JM, Dufton PA (1989) Alpha-2a interferon and vindesine in the treatment of advanced malignant melanoma. Cancer Immunol Immunother (Suppl) 28:Abstract 332Google Scholar
  33. 33.
    Grimm EA, Mazumder A, Zhang HZ et al. (1982) The lymphokine activated killer cell phenomenon: lysis of NKresistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841PubMedCrossRefGoogle Scholar
  34. 34.
    Gundersen S (1987) Dacarbazine, vindesine and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study. Cancer Treat Rep 71: 997–999PubMedGoogle Scholar
  35. 35.
    Hawkins MJ, Cune CS, Speyer JL, Sorell M (1984) Recombinant alpha-2 interferon (r/FN-alpha-2) (SCH 30500) in patients with metastatic malignant melanoma (MMM). An ECOG pilot study. Proc ASCO 3: 51Google Scholar
  36. 36.
    Hersey P, MacDonald M, Hall C et al. (1986) Immunological effects of recombinant interferon alpha-2a in patients with disseminated melanoma. Cancer 57: 1666–1674PubMedCrossRefGoogle Scholar
  37. 37.
    Horning SJ, Levine JF, Miller RA et al. (1982) Clinical and immunological effects of recombinant leukocyte interferon in eight patients with advanced cancer. J Am Med Ass 247: 1718CrossRefGoogle Scholar
  38. 38.
    Jacquillat C, Maral J, Chleq C, Banzet P (1985) Treatment of metastatic malignant melanoma (MMM) mit Roferon A “R” (Interferon Alpha Recombinant Roche). 3rd Eur Conf Clin Oncol Stockholm, June 16–20, p 183Google Scholar
  39. 39.
    Johnson DH, Presant C, Einhorn et al. (1985) Cisplatin, vinblastine and bleomycin in the treatment of metastatic melanoma: a phase II study of the South-eastern Study Group. Cancer Treat Rep 69: 821–824PubMedGoogle Scholar
  40. 40.
    Jose DG, Minty CCJ, Hillcoat BL (1985) Treatment of patients with disseminated malignant melanoma with bleomycin, oncovin, lomustine and DTIC (BOLD). Ist Int Conf Skin Melanoma, may 6–9, Venice (abstr 151 )Google Scholar
  41. 41.
    Jost LM, Gmur J, Oelz O, Sauter C, Stahel RA (1989) Immuntherapie von Tumoren mit Interleukin-2 und Lymphokin- aktivierten Killerzellen. Schweiz Med Wschr 119: 137–143Google Scholar
  42. 42.
    Karakousis CP, Didolkar MS, Lopez R. (1979) Chemoimmunotherapy ( DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma. Cancer Treat Rep 63: 1739–1943Google Scholar
  43. 43.
    Keilholz U, Welters H, Dummer R, Tilgen W, Hunstein W (1988) Ein neuer Weg in der Behandlung metastasierender Melanome: adoptive Immuntherapie mit Lymphokin-aktivierten Killerzellen und Interleukin 2. Hautarzt 39:378– 381Google Scholar
  44. 44.
    Kirkwood JM, Ernstoff M (1985) Melanoma therapeutic options with recombinant interferon. Semin Oncol (suppl 5 ) 12: 7–12Google Scholar
  45. 45.
    Kirkwood JM, Ernstoff M, Davis CA et al. (1985) Comparison of intramuscular and intravenous recombinant alpha- 2 interferon in melanoma and other cancers. Ann Intern Med 103: 32–36PubMedGoogle Scholar
  46. 46.
    Knost JA, Reynolds V, Grevo Fa et al. (1982) Adjuvant chemoimmunotherapy stage I/II malignant melanoma. J Surg Oncol 19: 1965–1970CrossRefGoogle Scholar
  47. 47.
    Koh HK, Sober AJ, Harmon DC et al. (1985) Adjuvant therapy of cutaneous malignant melanoma a critical review. Med Pediatr Oncol 13: 244–260PubMedCrossRefGoogle Scholar
  48. 48.
    Kokoschka EM, Trautinger F, Micksche M, Kokoschka R (1989) Long-term adjuvant therapy of high risk malignant melanoma with recombinant interferon alpha-2b. J Invest Dermatol 93: 560Google Scholar
  49. 49.
    Koyama Y (1984) Pharmacokinetics and clinical trials of HUifn-ß in malignant tumors. In: Kishida T (ed) Interferons, pp 189–195Google Scholar
  50. 50.
    Krown SE, Burke M, Kirkwood JM. (1984) Human leukocyte (alpha) interferon in metastatic malignant melanoma. Am Cancer Soc Phase II Trial. Cancer Treat Rep 68: 723–726Google Scholar
  51. 51.
    Kuzmits R, Kokoschka EM, Micksche M et al. (1985) Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma. Oncology 42: 46–32CrossRefGoogle Scholar
  52. 52.
    Landthaler M, Geyer C, Papendiek U, Braun-Falco O (1987) Alpha-2-Interferon-Therapie des metastasierenden malignen Melanoms. Dt Med Wschr 112: 919–921CrossRefGoogle Scholar
  53. 53.
    Legha SS, Papadopoulos NEJ, Plager C. (1987) Clinical evaluation of recombinant interferon alpha-2A ( Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 5: 1240–1246Google Scholar
  54. 54.
    Lejeune GJ, Macher E, Kleeberg U et al. (1988) An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase III adjuvant study. EORTC protoeol 18761. Eur J Cancer Clin Oncol (Suppl 2 ) 24: 81–90Google Scholar
  55. 55.
    Lichtin A, Illopoulos D, Guerry D, Eider D, Herlyn D, Steplewski Z (1988) Therapy of melanoma with a antimelanoma ganglioside monoclonal antibody: a possible mechanism of a complete response. Proc Am Soc Clin Oncol 7: 958AGoogle Scholar
  56. 56.
    Luikart SD, Kennealy GT, Kirkwood JM (1984) Randomized phase III trial of vinblastine and cis-chlorodiamineplatinum versus dacarbazine in malignant melanoma. J Clin Oncol 2: 164–168PubMedGoogle Scholar
  57. 57.
    McLeod GRC, Thomson DB, Hersey P (1987) Recombinant interferon alpha-2a in advanced malignant melanoma: a phase I—II study in combination with DTIC. Int J Cancer (Suppl l): 31–35Google Scholar
  58. 58.
    Melch Z, Krejci P (1983) Cis-diamine dichloroplatinum in the treatment of disseminated malignant melanoma. Neoplasma 30: 371–377Google Scholar
  59. 59.
    Mitchell MS, Kempf RA, Harel W et al. (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low dose intravenous interleukin 2 in disseminated melanoma. J Clin Oncol 6: 409–424PubMedGoogle Scholar
  60. 60.
    Mitchel MS, Kan-Mitchel J, Kempf RA, Harel W, Shau H, Lind S (1988) Active specific immunotherapy for melanoma: Phase I trial of allogenic lysates and a novel adjuvant. Cancer Res 48: 5883–5893Google Scholar
  61. 61.
    Mulder NH, Sleijfer DT, Smith JM. (1986) Phase II study of bleomycin, actinomycin D, DTIC and vindesin in disseminated malignant melanoma. Eur J Cancer Clin Oncol 22: 879–881Google Scholar
  62. 62.
    Nagel K, Junginger Th (1987) Extremitätenperfusion beim malignen Melanom. Dt Med Wschr 112: 1626–1629CrossRefGoogle Scholar
  63. 63.
    Nathanson L, Kaufmann SD, Carey RE (1981) Vinblastine, bleomycin and cis-dichlorodiamine-platinum chromotherapy in metastatic melanoma. Cancer 48: 1290–1294PubMedCrossRefGoogle Scholar
  64. 64.
    National Cancer Institute of Canada Melanoma Group (1984) Vinblastine, bleomycin and cisplatinum for the treatment of metastatic malignant melanoma. J Clin Oncol 2: 131–134Google Scholar
  65. 65.
    Orfanos CE, Garbe C, Bertz J (1985) Epidemiologie des malignen Melanoms der Haut im internationalen Vergleich. Hautarzt (Suppl VII): 81–84Google Scholar
  66. 66.
    Orfanos CE, Garbe C, Karg CH (1990) Chemotherapie des München, S 222–231Google Scholar
  67. 67.
    Papadopoulos NEJ, Howard JB, Murray JL, Cunningham J, Plager G, Legha S, Reußen J, Guttermann JU, Benjamin RS (1990) Phase 2 DHC and interleukin 2 (11-2) trial for metastatic malignant melanoma. Proceedings of ASCO Vol 9: 277 (A)Google Scholar
  68. 68.
    Retsas R, Newton RA, Westbury G (1979) Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother Pharmacol 2: 257 - 260PubMedCrossRefGoogle Scholar
  69. 69.
    Robinson WA, Kirkwood J, Harvay H. (1984) Effective use of recombinant human alpha-2 interferon (rIFN-alpha-2) in metastatic malignant melanoma (MMM). Proc ASCO 3:abstract C234Google Scholar
  70. 70.
    Rosenberg SA, Packard BS, Aebersold PM et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl J Med 319: 1676–1680PubMedCrossRefGoogle Scholar
  71. 71.
    Rosenberg SA, Spiess P, Lafrenieree R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1321PubMedCrossRefGoogle Scholar
  72. 72.
    Rosenberg SA, Lotze MT, Mull LM et al. (1985) Observat i on on the systemic administration of autologous lymphokine- activated killer cells and recombinant interleukin- 2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492PubMedCrossRefGoogle Scholar
  73. 73.
    Rosenberg SA, Lotze MT, Mull LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokines activated killer cells and interleukin- 2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897PubMedCrossRefGoogle Scholar
  74. 74.
    Ruppert P, Trommer H, Prott E-J, Budde J (1990) Adjuvante Therapie des malignen Melanoms mit IFN-beta im Stadium I. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. W. Zuckschwerdt Verlag, München, S 276–284Google Scholar
  75. 75.
    Rustin GJS, Dische S, deGaris ST, Nelstop A (1988) Treatment of advanced malignant melanoma with interferon alpha and etretinate. Eur J Cancer Clin Oncol 24:783- 784Google Scholar
  76. 76.
    Schiller JH, Willson JKV, Bittner G, Wolbert WH, Hawkins MJ, Borden ED (1986) Antiproliferative effects of interferons on human melanoma cells in the human tumor colony forming assay. J IFN Res 6: 615–625Google Scholar
  77. 77.
    Seigier HF, Lucas VS, Pickett NJ, Huang AT (1989) DTIC, CCNU, bleomycin and vincristine ( BOLD) in metastatic melanoma. Cancer 46: 2346–2348Google Scholar
  78. 78.
    Shea TC, Antman KH, Eder JP. (1988) Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and antalogous bone marrow support. Arch Dermatol 124: 878–884Google Scholar
  79. 79.
    Smith IE, Hedley DW, Powles TJ, McElwain TJ (1978)Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma and other tumors. Cancer Treat Rep 62: 1427–1433Google Scholar
  80. 80.
    Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B (1988) Clinical and immunological effects of recombinant interleukin given by repetitive weekly cycles to patients with cancer. Cancer Res 48: 615–625Google Scholar
  81. 81.
    Spiess P, Yang JC, Rosenberg SA (1987) In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant IL-2. JNCI 79: 1067–1075PubMedGoogle Scholar
  82. 82.
    Stadler R, Bratzke B, Mayer da Silva A, Orfanos CE (1988) Therapie des AIDS-induzierten Kaposi-Sarkoms und des malignen Melanoms mit Interferonen. Onkologie 11: 166–176PubMedCrossRefGoogle Scholar
  83. 83.
    Stadler R, Bratzke B, Orfanos CE (1987) Therapeutischer Einsatz von Interferon bei metastasierendem malignen Melanom, disseminiertem Kaposi-Sarkom und schwerem Morbus Behcet. Hautarzt 38: 453–460PubMedGoogle Scholar
  84. 84.
    Stadler R, Garbe C (1990) Therapie des malignen Melanoms mit rekombinantem Interferon alpha. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. W. Zuckschwerdt Verlag, München, S 245–252Google Scholar
  85. 85.
    Stadler R, Garbe C (1990) Neuere Therapieansätze beim disseminierten malignen Melanom. In: Orfanos CE, Garbe C (Hrsg) Das maligne Melanom der Haut. W. Zuckschwerdt Verlag, München, S 236–242Google Scholar
  86. 86.
    Stadler R, Garbe C, Bratzke B, Orfanos CE (1988) Klinische Erfahrungen bei der Therapie des malignen Melanoms mit Interferon. In: Schmoll HJ, Schröpf E (Hrsg) Lokale und systemische Chemotherapie mit Interferonen. Akt Immunol IV. Zuckschwerdt, München Bern Wien San Francisco, pp 62–71Google Scholar
  87. 87.
    Stadler R, Müller R, Orfanos CE (1986) Effect of recombinant alpha-a interferon on DNA-synthesis and differentiation of human keratinocytes in vitro. Br J Dermatol 114: 273–277PubMedCrossRefGoogle Scholar
  88. 88.
    Stadler R, Mayer-da-Silva A, Bratzke G, Garbe C, Orfanos CE (1989) Interferons in Dermatology. J Am Acad Dermatol 20 (4): 650–656PubMedCrossRefGoogle Scholar
  89. 89.
    Sterchi JM, Wells HB, Case LD et al. (1985) A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and stage II cutaneous melanoma. An interim report. Cancer 55: 707: 712Google Scholar
  90. 90.
    The Prudente Foundation Melanoma Study Group (1989) Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU and DTIC (BOLD regimen). Cancer 63: 1676–1680Google Scholar
  91. 91.
    Thomson DB, McLeod GR (1984) Pilot efficacy study of recombinant leukocyte A interferon (Ro 22-8181, IFNalpha- A) in patients with metastatic melanoma. Proc ASCO 3: 47Google Scholar
  92. 92.
    Veronesi U, Adamus J, Aubert C et al. (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307: 913–916PubMedCrossRefGoogle Scholar
  93. 93.
    Verschraegen CF, Kleeberg UR, Ulder J et al. (1988) Combination of cisplatin, vindesine and dacarbazine in advanced malignant melanoma. Cancer 62: 1061–1065PubMedCrossRefGoogle Scholar
  94. 94.
    Voigt H, Kleeberg UR (1986) Regionale und systemische Chemotherapie des Melanoms. Tumor Diagnostik & Therapie 7: 129–133Google Scholar
  95. 95.
    von Wussow P, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma Cancer 61: 1071–1074Google Scholar
  96. 96.
    von Wussow P, Hartmann F, Block B. (1987) Treatment of advanced malignant melanoma with dacarbazine,vindesine and cisplatin (DVP). Presented at the 4th Eur Conf Clin Oncol and Cancer Nursing, Madrid, 1–4 November, p 907Google Scholar
  97. 97.
    Vorobiof DA, Sarli R, Falkson G (1986) Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma. Cancer Treat Rep 70: 927–928PubMedGoogle Scholar
  98. 98.
    Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents agonist experimental and human malignancies: a review. Cancer Research 50: 3473–3486PubMedGoogle Scholar
  99. 99.
    West WH, Tauer KW, Yannelli JR et al. (1987) Constant infusion interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905PubMedCrossRefGoogle Scholar
  100. 100.
    Whitehead RP, Friglin R, Citron ML, Pfile J, Moton D, Patel D, Jones G, Levitt D (1990) A phase 2 study of concomitant recombinant human interleukin 2 (11-2) and recombinant interferon alpha-2a (Alpha-IFN) in patients with disseminated malignant melanoma. Proceedings of ASCO vol 9: 276 (A)Google Scholar
  101. 101.
    Wolf CH, Steiner A, Pehamberger H, Wolff K (1986) Interferon treatment (rlFN-alpha, rlFN-gamma and rlFN-alpha + Cimetidine) in metastatic melanoma. Abstracts AIO + EORTC Int Symposium on Malignant Melanoma, Hamburg, Sept 1986, abstract V - 8Google Scholar
  102. 102.
    Young DW, Lever RS, English JSC, Mackie RM (1985) The use of BELD combination therapy (bleomycin, vindesine, CCNU and DTIC) in advanced malignant melanoma. Cancer 55: 1879–1881Google Scholar
  103. 103.
    Zouboulis CH, Garbe C, Orfanos CE (1989) Wachstumshemmung von Melanomzellen durch Interferone in vitro.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Rudolf Stadler
    • 1
  • Constantin E. Orfanos
    • 2
  1. 1.Hautklinik, im Klinikum MindenMindenGermany
  2. 2.Hautklinik und PoliklinikKlinikum Steglitz, der Freien Universität BerlinBerlinGermany

Personalised recommendations